B
27.49
-0.18 (-0.65%)
| Penutupan Terdahulu | 27.67 |
| Buka | 27.90 |
| Jumlah Dagangan | 1,404,756 |
| Purata Dagangan (3B) | 2,050,909 |
| Modal Pasaran | 5,195,335,168 |
| Harga / Jualan (P/S) | 22.77 |
| Julat 52 Minggu | |
| Tarikh Pendapatan | 20 Feb 2025 - 24 Feb 2025 |
| Margin Keuntungan | -201.53% |
| Margin Operasi (TTM) | -6,849.52% |
| EPS Cair (TTM) | -2.42 |
| Pertumbuhan Hasil Suku Tahunan (YOY) | -33.20% |
| Nisbah Semasa (MRQ) | 3.19 |
| Aliran Tunai Operasi (OCF TTM) | -450.22 M |
| Aliran Tunai Bebas Leveraj (LFCF TTM) | -365.12 M |
| Pulangan Atas Aset (ROA TTM) | -48.88% |
Arah Aliran Pasaran
| Jangka Pendek | Jangka Sederhana | ||
| Industri | Biotechnology (US) | Bercampur | Bercampur |
| Biotechnology (Global) | Bercampur | Bercampur | |
| Stok | BridgeBio Pharma, Inc. | Menaik | Menaik |
AISkor Stockmoo
1.3
| Konsensus Penganalisis | 5.0 |
| Aktiviti Orang Dalam | 3.0 |
| Volatiliti Harga | -2.0 |
| Purata Bergerak Teknikal | 0.0 |
| Osilator Teknikal | 0.5 |
| Purata | 1.30 |
|
BridgeBio Pharma is a biotechnology company focused on discovering, developing, testing, and delivering transformative treatments for patients with genetic diseases. The company has four programs in its late-stage pipeline focusing on Mendelian disorders, oncology, and gene therapy. One of its key programs, acoramidis (AG10), is an orally administered small molecule designed to stabilize tetrameric transthyretin for the treatment of transthyretin amyloid cardiomyopathy. |
|
| Sektor | Healthcare |
| Industri | Biotechnology |
| Gaya Pelaburan | Small Growth |
| % Dimiliki oleh Orang Dalam | 5.40% |
| % Dimiliki oleh Institusi | 94.45% |
| Julat 52 Minggu | ||
| Julat Harga Sasaran | ||
| Tinggi | 49.00 (HC Wainwright & Co., 78.25%) | Beli |
| Median | 47.00 (70.97%) | |
| Rendah | 45.00 (B of A Securities, 63.70%) | Beli |
| Purata | 47.00 (70.97%) | |
| Jumlah | 4 Beli | |
| Harga Purata @ Panggilan | 27.07 | |
| Syarikat | Tarikh | Harga Sasaran | Panggilan | Harga @ Panggilan |
|---|---|---|---|---|
| HC Wainwright & Co. | 16 Dec 2024 | 49.00 (78.25%) | Beli | 27.71 |
| 25 Nov 2024 | 49.00 (78.25%) | Beli | 27.19 | |
| B of A Securities | 25 Nov 2024 | 45.00 (63.70%) | Beli | 27.19 |
| Scotiabank | 25 Nov 2024 | 48.00 (74.61%) | Beli | 27.19 |
| 15 Nov 2024 | 45.00 (63.70%) | Beli | 23.72 | |
| Leerink Partners | 17 Oct 2024 | 46.00 (67.33%) | Beli | 26.19 |
| Nama | Purata Belian ($) | Purata Jualan ($) | Jumlah Net | Jumlah Nilai Bersih ($) |
|---|---|---|---|---|
| TRIMARCHI THOMAS | 29.04 | - | 50,000 | 1,452,000 |
| Jumlah Keseluruhan Kuantiti Bersih | 50,000 | |||
| Jumlah Keseluruhan Nilai Bersih ($) | 1,452,000 | |||
| Purata Pembelian Keseluruhan ($) | 29.04 | |||
| Purata Jualan Keseluruhan ($) | - | |||
| Nama | Pemegang | Tarikh | Jenis | Kuantiti | Harga | Nilai ($) |
|---|---|---|---|---|---|---|
| TRIMARCHI THOMAS | Pegawai | 10 Dec 2024 | Diperolehi (+) | 50,000 | 29.04 | 1,452,000 |
Tahap sokongan, rintangan dan garis aliran yang dibentangkan telah dihasilkan oleh model kecerdasan buatan (AI) dan harus ditafsirkan dengan berhati-hati.
Portfolio
| Keuntungan Nyata | - |
| Keuntungan Tidak Nyata | - |
| Dividen Diterima 2024 | - |
| Jumlah Untung | - |
| Pulangan Purata | - |
| Kuantiti (Beli) | - |
| Purata Harga (Beli) | - |
| Kuantiti (Jual) | - |
| Purata Harga (Jual) | - |